Active Biotech AB (SE:ACTI)
:ACTI
Want to see SE:ACTI full AI Analyst Report?
ACTI Stock Chart & Stats
kr0.04
<kr0.01(1.97%)
At close: 4:00 PM EST
kr0.04
<kr0.01(1.97%)
Day’s Range― - ―
52-Week Rangekr0.04 - kr0.27
Previous CloseN/A
Volume903.68K
Average Volume (3M)4.56M
Market Cap
kr189.27M
Enterprise Valuekr36.79M
Total Cash (Recent Filing)kr53.30M
Total Debt (Recent Filing)kr100.00K
Price to Earnings (P/E)―
Beta0.04
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding2,636,067,100
10 Day Avg. Volume2,218,804
30 Day Avg. Volume4,558,826
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.11
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Financial FlexibilityVery low leverage materially reduces default and refinancing risk for a cash-burning biotech. Minimal debt provides structural flexibility to absorb R&D setbacks, pursue partnerships or milestone financing, and delay dilutive equity raises while clinical programs advance over the next several months.
Improving Loss TrendA marked narrowing of net losses indicates the company is making operational progress or managing costs more effectively. If this structural improvement continues, it reduces near-term cash needs, enhances runway planning, and strengthens negotiating positions for partnerships or milestone-based financings.
Focused R&D And Partnership StrategyA strategy centered on small-molecule R&D plus partnering for late-stage development is asset-light and scalable. By outsourcing commercialization costs, the company can extend cash runway, de-risk late-stage capital outlays, and monetize programs via milestone and royalty structures over the medium term.
Bears Say
No Revenue And Persistent Heavy LossesAbsence of revenue and ongoing heavy losses mean the business lacks operating cash generation. This structural deficit forces reliance on external funding, constrains strategic flexibility, and makes continued R&D progress contingent on successful financings or partner deals in the coming 2–6 months.
Sustained Negative Operating And Free Cash FlowMaterial negative operating cash flow and FCF reflect ongoing cash burn that must be financed externally. This structural cash deficit increases dilution risk, pressures milestone timing, and could force cutbacks or delayed trials if capital markets or partner funding is slow to materialize.
Eroding Equity BaseA falling equity base reduces the balance-sheet buffer against continued losses and increases vulnerability to adverse outcomes. Structurally, declining shareholders’ equity elevates the likelihood and potential frequency of dilutive capital raises, constraining strategic options over the medium term.
Active Biotech AB News
ACTI FAQ
What was Active Biotech AB’s price range in the past 12 months?
Active Biotech AB lowest stock price was kr0.04 and its highest was kr0.27 in the past 12 months.
What is Active Biotech AB’s market cap?
Active Biotech AB’s market cap is kr189.27M.
When is Active Biotech AB’s upcoming earnings report date?
Active Biotech AB’s upcoming earnings report date is Aug 20, 2026 which is in 90 days.
How were Active Biotech AB’s earnings last quarter?
Active Biotech AB released its earnings results on May 07, 2026. The company reported -kr0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.003.
Is Active Biotech AB overvalued?
According to Wall Street analysts Active Biotech AB’s price is currently Overvalued.
Does Active Biotech AB pay dividends?
Active Biotech AB does not currently pay dividends.
What is Active Biotech AB’s EPS estimate?
Active Biotech AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Active Biotech AB have?
Active Biotech AB has 2,636,067,100 shares outstanding.
What happened to Active Biotech AB’s price movement after its last earnings report?
Active Biotech AB reported an EPS of -kr0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.333%.
Which hedge fund is a major shareholder of Active Biotech AB?
Currently, no hedge funds are holding shares in SE:ACTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Active Biotech AB
Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1983 and is headquartered in Lund, Sweden.
Technical Analysis
Medivir AB
―
Isofol Medical AB
―
Xintela AB
―
Elicera Therapeutics AB
―
IRLAB Therapeutics AB Class A
―